A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages

Because of the rapid mutation and high airborne transmission of SARS‐CoV‐2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor‐binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD‐targeted type IV...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiantao, Wu, Shijian, Liu, Jie, Chen, Ran, Zhang, Yongli, Lin, Yingtong, Xi, Zhihui, Deng, Jieyi, Pu, Zeyu, Liang, Chaofeng, Feng, Jinzhu, Li, Rong, Lin, Keming, Zhou, Mo, Liu, Yingying, Zhang, Xu, Liu, Bingfeng, Zhang, Yiwen, He, Xin, Zhang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520630/
https://www.ncbi.nlm.nih.gov/pubmed/37526323
http://dx.doi.org/10.1002/advs.202301034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520630/
https://www.ncbi.nlm.nih.gov/pubmed/37526323
http://dx.doi.org/10.1002/advs.202301034

Ejemplares similares